HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO LXJ International Holdings - The Pain Points and the Outlook

Pre-IPO Bama Tea - The Business Model, the Challenges and the Outlook

Pre-IPO 52TOYS Development - The Business Model and the Concerns Behind

Pre-IPO Kayou - The Strength of Business Model and the Potential Risks Behind

Pre-IPO Fujian Lemo IoT Technology - The Outlook for Growth and Profit Margins Is Not Optimistic

Equity Capital Markets

Atom Therapeutics / Equity Capital Markets

<ul>
<li>The global population of gout and hyperuricemia patients is large and there's unmet needs.However, if competition is fierce or medical insurance restrictions are imposed, ABP-671's peak sales could be RMB1-2bn.</li>
<li>The potential of ABP-745 depends on whether its safety and efficacy advantages can be confirmed in later-stage clinical trials. Depending on indications expansion, peak sales could be RMB500 million-1.5 billion.</li>
<li>Post-Money valuation of Atom after Series D Financing is about RMB3.05 billion. A comfortable valuation range could be RMB4-6 billion if based on the commercialization of ABP-671 and ABP-745.</li>
</ul>


The global population of gout and hyperuricemia patients is large and there's unmet needs.However, if competition is fierce or medical insurance restrictions are imposed, ABP-671's peak sales could be RMB1-2bn.
The potential of ABP-745 depends on whether its safety and efficacy advantages can be confirmed in later-stage clinical trials. Depending on indications expansion, peak sales could be RMB500 million-1.5 billion.
Post-Money valuation of Atom after Series D Financing is about RMB3.05 billion. A comfortable valuation range could be RMB4-6 billion if based on the commercialization of ABP-671 and ABP-745.


Pre-IPO Atom Therapeutics - About The Pipeline and the Concerns Behind